Ibrutinib for chronic lymphocytic leukemia in the setting of respiratory failure from severe COVID‐19 infection: Case report and literature review

Abstract Ibrutinib, a known Burton's tyrosine kinase (BTK) and interleukin‐2 inducible T‐cell kinase (ITK) inhibitor, is used for the treatment of B‐cell disorders (chronic lymphocytic leukemia [CLL] and various other lymphomas) and chronic graft versus host disease following allogeneic hematopoieti...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Adam Yuh Lin, Michael J. Cuttica, Michael G. Ison, Leo I. Gordon
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2020-11-01
Edice:	eJHaem
Témata:	acute respiratory distress syndrome BTK inhibitor COVID‐19 chronic lymphocytic leukemia Ibrutinib
On-line přístup:	https://doi.org/10.1002/jha2.98
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!